Literature DB >> 10424833

A comparison of preference assessment instruments used in a clinical trial: responses to the visual analog scale from the EuroQol EQ-5D and the Health Utilities Index.

H A Glick1, D Polsky, R J Willke, K A Schulman.   

Abstract

OBJECTIVES: To compare preference assessments that were made by using the EuroQol EQ-5D and the Health Utilities Index Mark II.
SUBJECTS: 561 patients in a randomized trial of tirilazad mesylate for aneurysmal subarachnoid hemorrhage. MEASURES: Three preference assessments (a value score for the EuroQol instrument and value and utility scores for the Health Utilities Index) made three months after randomization. The averages for each of the three scores, stratified by clinical outcomes and attributes of the Health Utilities Index health status classification system, were compared. To evaluate potential sources of difference between the instruments, the authors estimated two alternative Health Utilities Index scoring rules that were based on patient responses to the EuroQol instrument.
RESULTS: Patients' ratings of their current health made by using the 100-point visual analog scale from the EuroQol instrument were more similar to the utility scores for the Health Utilities Index than they were to the value scores for the Health Utilities Index. The biggest differences between the visual analog scores for the EuroQol instrument and the utility scores for the Health Utilities index were seen at higher levels of functioning.
CONCLUSION: For states representing higher levels of functioning, differences were seen between patients' self-ratings obtained by using the EuroQol instrument and the patients' utility scores on the Health Utilities Index; for states representing lower levels of functioning, substantial agreement was observed between these two scores. Differences observed at the higher levels of functioning suggest that further research is needed to determine whether the Health Utility Index's assignment of a score of 1.0 to the reference state representing being healthy is appropriate.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10424833     DOI: 10.1177/0272989X9901900305

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  11 in total

1.  Comparison of the Health Utilities Index Mark 3 (HUI3) and the EuroQol EQ-5D in patients treated for intermittent claudication.

Authors:  J L Bosch; M G Hunink
Journal:  Qual Life Res       Date:  2000       Impact factor: 4.147

2.  Preference-Based EQ-5D index scores for chronic conditions in the United States.

Authors:  Patrick W Sullivan; Vahram Ghushchyan
Journal:  Med Decis Making       Date:  2006 Jul-Aug       Impact factor: 2.583

3.  Comparison of EQ-5D, HUI, and SF-36-derived societal health state values among spine patient outcomes research trial (SPORT) participants.

Authors:  Christine M McDonough; Margaret R Grove; Tor D Tosteson; Jon D Lurie; Alan S Hilibrand; Anna N A Tosteson
Journal:  Qual Life Res       Date:  2005-06       Impact factor: 4.147

4.  Cost-effectiveness of self-managed versus physician-managed oral anticoagulation therapy.

Authors:  Dean A Regier; Rubina Sunderji; Larry D Lynd; Kenneth Gin; Carlo A Marra
Journal:  CMAJ       Date:  2006-06-20       Impact factor: 8.262

5.  Construct validity of the EQ-5D in low-income Chinese American primary care patients.

Authors:  Erica I Lubetkin; Haomiao Jia; Marthe R Gold
Journal:  Qual Life Res       Date:  2004-10       Impact factor: 4.147

6.  Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial.

Authors:  Sanjiv J Shah; John F Heitner; Nancy K Sweitzer; Inder S Anand; Hae-Young Kim; Brian Harty; Robin Boineau; Nadine Clausell; Akshay S Desai; Rafael Diaz; Jerome L Fleg; Ivan Gordeev; Eldrin F Lewis; Valetin Markov; Eileen O'Meara; Bondo Kobulia; Tamaz Shaburishvili; Scott D Solomon; Bertram Pitt; Marc A Pfeffer; Rebecca Li
Journal:  Circ Heart Fail       Date:  2012-12-20       Impact factor: 8.790

7.  Community treatment orders and social outcomes for patients with psychosis: a 48-month follow-up study.

Authors:  Francis Vergunst; Jorun Rugkåsa; Constantinos Koshiaris; Judit Simon; Tom Burns
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2017-09-12       Impact factor: 4.328

8.  Continuity of care: validation of a self-report measure to assess client perceptions of mental health service delivery.

Authors:  Anthony S Joyce; Carol E Adair; T Cameron Wild; Gerald M McDougall; Alan Gordon; Norman Costigan; Gloria Pasmeny
Journal:  Community Ment Health J       Date:  2009-06-24

9.  Health-related quality of life and function in middle-aged individuals with thalidomide embryopathy.

Authors:  Shadi A Ghassemi Jahani; Jon Karlsson; Helena Brisby; Aina J Danielsson
Journal:  J Child Orthop       Date:  2016-11-16       Impact factor: 1.548

10.  Psychometric validation of a multi-dimensional capability instrument for outcome measurement in mental health research (OxCAP-MH).

Authors:  Francis Vergunst; Crispin Jenkinson; Tom Burns; Paul Anand; Alastair Gray; Jorun Rugkåsa; Judit Simon
Journal:  Health Qual Life Outcomes       Date:  2017-12-28       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.